UK markets close in 1 hour 38 minutes
  • FTSE 100

    7,487.21
    -31.14 (-0.41%)
     
  • FTSE 250

    20,079.61
    +14.02 (+0.07%)
     
  • AIM

    957.37
    -4.35 (-0.45%)
     
  • GBP/EUR

    1.1787
    -0.0047 (-0.40%)
     
  • GBP/USD

    1.2422
    -0.0070 (-0.56%)
     
  • BTC-GBP

    23,676.04
    -1,110.33 (-4.48%)
     
  • CMC Crypto 200

    657.94
    -12.74 (-1.90%)
     
  • S&P 500

    4,027.82
    -61.03 (-1.49%)
     
  • DOW

    32,229.59
    -425.00 (-1.30%)
     
  • CRUDE OIL

    112.85
    +0.45 (+0.40%)
     
  • GOLD FUTURES

    1,813.40
    -5.50 (-0.30%)
     
  • NIKKEI 225

    26,911.20
    +251.45 (+0.94%)
     
  • HANG SENG

    20,644.28
    +41.76 (+0.20%)
     
  • DAX

    14,093.15
    -92.79 (-0.65%)
     
  • CAC 40

    6,383.72
    -46.47 (-0.72%)
     

4basebio Plc - Director/PDMR Shareholding

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

12 May 2022

4basebio plc
(the "Company")

Directors’ Dealings

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, announces that, on 12 May 2022, directors of the Company purchased shares in the Company as follows:

Director

Total Number of shares Purchased

Average Price per Share (p)

Beneficial Holding Following Purchase

Beneficial Holding as a Percentage of Issued Share Capital

Heikki Lanckriet

3,000

470p

1,252,453

10.17%

David Roth

4,000

483.5p

312,000

2.53%

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio plc

+44 (0)12 2396 7943

Heikki Lanckriet, CEO

Cairn Financial Advisers LLP (Nominated Adviser)

+44 (0)20 7213 0880

Jo Turner / Sandy Jamieson

finnCap Ltd (Broker)

+44 (0)20 7220 0500

Geoff Nash/Richard Chambers/Charlotte Sutcliffe

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1. Details of the person discharging managerial responsibilities/person closely associated

  1. Name

1. Heikki Lanckriet

2. David Roth

2. Reason for notification

  1. Position/Status

1. Chief Executive Office

2. Chief Financial Officer

b. Initial notification/ Amendment Initial

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

  1. Name 4basebio plc

b. LEI 213800E2DX9EAIUNCB30

4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

  1. Description of the financial instrument, type Ordinary Shares of instrument

    Identification Code ISIN: GB00BMCLYF79

  2. Nature of the transaction Acquisition of ordinary shares

  3. Price(s) and volume(s) Volume(s) Price (p)

  1. 3,000 470p

  2. 3,000 480p

d. Aggregated information

1.
- Aggregated Volume 3,000
- Price 470p pence per share

2.
- Aggregated Volume 4,000
- Price 483.5p pence per share

e. Date of the transaction 12/05/2022

f. Place of the transaction London Stock Exchange, AIM

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting